Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Acrux Limited is an Australian specialty pharmaceutical company focused on developing and commercializing topical drug delivery technologies, primarily transdermal formulations. The company has historically relied on royalty revenues from licensed products, but faces severe financial distress with near-zero revenue generation, negative operating cash flow, and an 85% stock decline over the past year, indicating potential business model failure or loss of key licensing agreements.
Acrux historically operated an asset-light model by developing proprietary transdermal drug delivery technologies and out-licensing them to larger pharmaceutical companies for commercialization, earning royalties on product sales and milestone payments. The 76.6% revenue decline and negative operating margin of -754% suggest loss of major licensing agreements, product discontinuations by partners, or patent expirations. With 100% gross margin but massive operating losses, the company appears to be burning through cash on R&D or administrative costs without corresponding revenue generation. The 3.55 debt-to-equity ratio and 1.07 current ratio indicate precarious liquidity positioning.
Announcements of new licensing agreements or partnerships with pharmaceutical companies for transdermal product candidates
Regulatory approvals or rejections for licensed products in key markets (FDA, EMA, TGA)
Royalty revenue trends from existing licensed products, indicating commercial success or failure of partner-marketed drugs
Patent litigation outcomes or intellectual property challenges affecting core transdermal delivery technology
Capital raising announcements or going-concern warnings given severe cash burn and minimal revenue
Partner dependency risk: Revenue entirely dependent on pharmaceutical partners' commercial execution, marketing investment, and strategic priorities, with no direct control over product success
Patent cliff exposure: Transdermal delivery patents have finite lives, and expiration of core intellectual property would eliminate competitive moat and royalty streams
Regulatory pathway complexity: Transdermal formulations face stringent bioequivalence and safety requirements, with high probability of development failures or approval delays
Small-cap biotech liquidity crisis: Sector-wide funding challenges for pre-revenue or low-revenue biotechs may prevent capital raises needed for survival
Alternative delivery technologies: Oral, injectable, or novel delivery systems (microneedles, iontophoresis) may obviate need for traditional transdermal patches
Generic competition: Once patents expire, generic manufacturers can replicate transdermal formulations, eliminating royalty revenue
In-house development by pharma partners: Large pharmaceutical companies may develop proprietary transdermal capabilities, reducing reliance on external licensing
Going concern risk: With -$0.0B operating cash flow, minimal revenue, and 1.07 current ratio, the company faces imminent liquidity crisis without successful capital raise
Debt burden: 3.55 debt-to-equity ratio is unsustainable given negative cash generation, creating refinancing risk and potential covenant breaches
Negative equity trajectory: -268% ROE indicates rapid equity destruction, with book value potentially approaching zero if losses continue
Dilution risk: Any equity financing at current depressed valuation would be massively dilutive to existing shareholders
low - Pharmaceutical demand is generally non-discretionary and recession-resistant, but Acrux's reliance on partner companies' commercialization decisions and healthcare system formulary access creates indirect exposure. Economic downturns may delay partner investment in product launches or reduce prescription volumes for non-essential dermatological or hormonal treatments. However, the company's current distress appears idiosyncratic rather than macro-driven.
Rising interest rates negatively impact Acrux through multiple channels: (1) higher discount rates compress valuations for unprofitable biotech companies with distant cash flow expectations, (2) increased cost of capital makes financing operations more expensive given likely need for equity or debt raises, (3) stronger USD (typically correlated with rate hikes) reduces AUD-translated value of any USD-denominated royalties. With negative cash flow and high debt load, refinancing risk increases in higher-rate environments.
High exposure given 3.55 debt-to-equity ratio and negative operating cash flow. The company likely faces challenges refinancing existing debt or accessing additional credit facilities without dilutive equity raises. Tightening credit conditions would severely constrain operational flexibility and potentially force asset sales, licensing deals on unfavorable terms, or insolvency proceedings. Lender covenants may be at risk given deteriorating financial metrics.
Speculative distressed/turnaround investors or biotech specialists willing to accept binary outcomes. The 85% one-year decline, negative cash flow, and minimal market cap suggest this is a high-risk restructuring or liquidation candidate rather than a core holding for institutional investors. Typical shareholders would be Australian retail investors with legacy positions, distressed debt funds analyzing recovery value, or biotech-focused hedge funds making asymmetric bets on partnership announcements or acquisition. Not suitable for value, dividend, or conservative growth investors.
extreme - The stock exhibits characteristics of a distressed micro-cap biotech with binary event risk. The 55% decline over both three-month and six-month periods indicates sustained selling pressure rather than normal volatility. Expect continued high volatility driven by: (1) liquidity events (capital raises, debt restructuring), (2) partnership announcements, (3) regulatory decisions, (4) going-concern assessments. Beta likely exceeds 2.0 relative to broader market, with idiosyncratic risk dominating systematic factors.
